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Abstract
Introduction: The literature on surgical salvage, i.e. lung resections in patients who develop a local recurrence
following stereotactic ablative radiotherapy (SABR), is limited. We describe our experience with salvage surgery in
nine patients who developed a local recurrence following SABR for early stage non-small cell lung cancer (NSCLC).
Methods: Patients who underwent surgical salvage for a local recurrence following SABR for NSCLC were identified
from two Dutch institutional databases. Complications were scored using the Dindo-Clavien-classification.
Results: Nine patients who underwent surgery for a local recurrence were identified. Median time to local
recurrence was 22 months. Recurrences were diagnosed with CT- and/or 18FDG-PET-imaging, with four patients
also having a pre-surgical pathological diagnosis. Extensive adhesions were observed during two resections,
requiring conversion from a thoracoscopic procedure to thoracotomy during one of these procedures. Three
patients experienced complications post-surgery; grade 2 (N = 2) and grade 3a (N = 1), respectively. All resection
specimens showed viable tumor cells. Median length of hospital stay was 8 days (range 5–15 days) and 30-day
mortality was 0 %. Lymph node dissection revealed mediastinal metastases in 3 patients, all of whom received
adjuvant therapy.
Conclusions: Our experience with nine surgical procedures for local recurrences post-SABR revealed two grade IIIa
complications, and a 30-day mortality of 0 %, suggesting that salvage surgery can be safely performed after SABR.
Introduction
Surgery is the standard of care for operable patients
with early stage non-small cell lung cancer (NSCLC).
Stereotactic ablative radiotherapy (SABR) is the rec-
ommended therapy in patients unfit for surgery, as
well as for patients who decline surgery [1, 2].
Approximately 10 % of patients who undergo SABR to
guideline-recommended doses will develop local tumor
recurrences [3]. A growing number of reports have ad-
dressed salvage surgery following SABR for early stage
lung cancer [4 – 9]. All but one of the published reports
on surgical salvage post-SABR have originated from
Japanese centers, with one possibly being an update of a
previous report [4]. This suggests that the available litera-
ture represents only between 22–27 patients in total. En-
couragingly, the 5-year overall survival (OS) in 12 patients
who underwent salvage surgery in the largest reported
series to date, was 80 % [5]. As the number of potentially
operable patients undergoing SABR continues to increase
[6], we analyzed the outcomes of salvage surgery in a co-
hort of Dutch patients who experienced local failure fol-
lowing SABR for a primary early stage NSCLC.
Materials & methods
We queried the institutional databases at both the VU
University Medical Center (VUmc) and the Erasmus
Medical Center Rotterdam (EMCR), which represent
two of the earliest adopters of SABR for lung cancer in
the Netherlands [7, 8], in order to identify patients who
had undergone a surgical resection for a local recurrence
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following SABR for early stage NSCLC. We also con-
tacted surgeons from other major regional surgical cen-
ters to determine if they had operated on post-SABR
cases.
The delivery of lung SABR in the Netherlands is per-
formed in accordance with published guidelines [9].
Patients from the VUmc were treated to individualized
target volumes encompassing all motion on four-
dimensional CT scans, with no active motion manage-
ment [10]. Patients at the EMCR were treated using a
Cyberknife unit with real-time tumor tracking [8]. All
fractionation schemes had a biologically effective dose
of >100 Gy10 to the planning target volume (PTV). For
each patient, we retrospectively calculated the maximum
dose delivered to the proximal bronchial tree.
Post-SABR follow-up consisted of a contrast-enhanced
CT-scan of the thorax and abdomen carried out at 2–
3 months after treatment, 6-monthly for 2 years, and an-
nually thereafter. For patients followed up elsewhere,
their attending lung physicians and surgeons were con-
tacted for details of local recurrence, and any subsequent
surgery. Local failure was defined as a suspected recur-
rence in, or adjacent to, the PTV. The diagnosis of local
recurrence was based on CT and/or 18FDG PET scans,
and discussed within multi-disciplinary tumor boards.
Complications following surgery were classified using
the Dindo-Clavien classification [11]. The Dindo-Clavien
classification is a commonly used and validated classifica-
tion system for post-operative complications [12]. Follow-
up was calculated using the reverse Kaplan-Meier method
[13]. Time-to-event outcomes were analyzed using the
Kaplan–Meier method.
Results
Of 11 potential patients identified for further study, nine
patients were finally included in this report. One patient
was excluded as details of both the surgical procedure
and early post-operative course were unavailable, even
though this patient finally died of unrelated causes
39 months after salvage surgery. A second excluded pa-
tient had prior large-field conventional thoracic radio-
therapy, in addition to SABR. All nine patients had been
initially considered to be medically operable at the time
of diagnosis (Table 1), but had been referred for SABR
following discussions at a multidisciplinary tumor board,
and with patients themselves. Six of these patients had
undergone their SABR procedure at the VUmc, one at
the EMCR, and one each at two other Dutch centers.
The median Charlson co-morbidity index [14] at initial
presentation was 2 (range 1 - 4). All patients initially pre-
sented with peripheral tumors, with a mean diameter of
27 mm (SD ± 3.5 mm), and a median planning target
volume (PTV) of 23.9 mm3 (range 9.2 – 243 mm3). The
maximum total dose to the ipsilateral proximal bronchial
tree on the SABR plan was below 30 Gy in all patients,
and below 20 Gy in all but one patient.
Median time to diagnosis of local recurrence following
SABR, which was determined after discussion at multidis-
ciplinary tumor boards, was 22 months (range 10–
35 months). At time of recurrence, all patients had a pro-
gressive lesion on consecutive CT-scans, which showed
local uptake on 18FDG-PET scans. Pulmonary function
tests before surgery revealed a mean predicted FEV1% of
71 % ± 21 %. Pre-operative pathology-confirmation of
local recurrence was made in 4 patients, with another
patient having suspicious endobronchial cytology. As
assessed on 18FDG-PET scans, seven patients had an
isolated local recurrence, one patient had a synchronous
solitary adrenal gland metastasis in addition to the local
recurrence, and another patient showed a histologically
confirmed recurrence in a hilar node.
Details of the surgical procedures performed are sum-
marized in Table 2. Six patients underwent a lobec-
tomy, of which one procedure was a full video-assisted
thoracoscopic procedure (VATS). Another planned VATS
Table 1 Patient characteristics
Patients undergoing salvage
surgery (N = 9)
N (%) or Median (range)
Age (years) 65 (54–71)
Gender
- Male
- Female
6 (67 %)
3 (33 %)
Tumor location
- Left upper lobe
- Left lower lobe
- Right upper lobe
- Right middle lobe
1 (11 %)
4 (44 %
3 (33 %)
1 (11 %)
Fractionation scheme
- 3 x 20 Gy
- 5 x 11 Gy
- 5 x 12 Gy
- 8 x 7.5 Gy
2 (22 %)
4 (44 %)
1 (11 %)
2 (22 %)
Diagnosis of LR
- CT + 18FDG-PET + path
- CT + 18FDG-PET
5 (56 %)
4 (44 %)
Time to local recurrence 22 months (10–35)
Initial tumor stage
- T1aN0M0
- T1bN0M0
- T2aN0M0
- T2bN0M0
4 (44 %)
2 (22 %)
2 (22 %)
1 (11 %)
Pathology prior to SABR
- Adenocarcinoma
- Squamous cell
- NSCLC not specified
- Not obtained
2 (22 %)
3 (33 %)
2 (22 %)
2 (22 %)
LR local recurrence, CT Computed tomography imaging, PET Positron emission
tomography imaging, Path pre-surgical pathology
Verstegen et al. Radiation Oncology  (2016) 11:131 Page 2 of 5
lobectomy was converted to an open pneumonectomy
when extensive peritumoral and pleural adhesions were
encountered. In yet another patient, a planned sleeve-
lobectomy was performed as a pre-operative hilar lymph
node metastasis had been identified. In one patient, an
intra-operative decision was made to perform only a
wedge-resection as the lesion was considered to be very
small.
No unexpected intra-operative findings were ob-
served in four of nine resections. Limited intra-thoracic
adhesions were observed in three patients, and exten-
sive adhesions were observed during two procedures.
Of the latter, one resulted in conversion into an open
pneumonectomy in a patient with extensive peritu-
moral and pleural adhesions, and tumor invasion into
pericardial fat. With the exception of the last case, a
complete (R0) resection was obtained in all patients.
The bronchial stump was covered with an intercostal
muscle flap in just one patient. Three patients experi-
enced grade 2 or higher complications following sur-
gery, which in two cases was due to an infection treated
with oral antibiotics (grade II complication). One other
patient developed a persistent airway leakage, which re-
quired a new thoracic tube (grade IIIa complication).
This was not the patient in who the bronchial stump
was covered using an intercostal muscle flap. None of
the patients developed a broncho-pleural fistel. The
median length of hospital stay was 8 days (range 5–
15 days) The resected sample revealed the presence of vi-
able tumor in all cases, with co-existing necrosis observed
in three patients, and fibrosis in four cases. The 30-day
mortality was 0 %. One patient died within 90 days follow-
ing surgery due to disease progression (90-day mortality
11 %).
Five patients had their disease upstaged during sur-
gery: two had a final diagnosis of a T3 tumor and three
had mediastinal lymph node metastases. All upstaged
patients underwent adjuvant therapy consisting of either
chemotherapy (n = 4) or radiotherapy (n = 1). Median
follow-up after surgery was 19 months, with only two
patients developing further disease-progression. Of the
latter, one developed regional failure, followed by distant
metastases, while the other patient developed distant
metastasis. Median overall survival for all patients was
26 months, a figure that should be interpreted with
caution given the small size of our patient group and the
relatively short period of follow-up.
Discussion
The main finding of our study in patients who under-
went salvage surgery following SABR for a peripheral
early-stage NSCLC, is that surgery is feasible with little
morbidity. The surgical procedures were generally not
complicated by SABR-induced fibrosis, except in one
patient in whom co-existing infiltrative tumor recur-
rence could have contributed to ‘adhesions’. However, it
should be noted that all nine patients had been consid-
ered fit to undergo surgery at the time of undergoing
SABR for their index tumor. Our findings can be placed
in context by considering SABR outcomes from the
VUMC institutional database, where six of the nine pa-
tients had been treated. Of the 855 patients from the
VUMC who underwent SABR for a stage I NSCLC, 46
developed a local recurrence, with actuarial local control
rates at 3 and 5 years being 92.4 and 90.9 %, respectively
[3]. Of these 46 patients, 54 % of local recurrences were
isolated events, while 13 % of patients developed both
local and regional recurrences. It has to be noted, how-
ever, that the majority of SABR patients treated at the
VUmc were considered to be medically inoperable, both
initially and at the time of disease recurrence. Overall,
ten patients underwent radical salvage treatment, includ-
ing the six patients described who underwent salvage
surgery.
All of our patients had received SABR doses which
were recommended in the ESMO guidelines, namely
that of a minimum biological dose of 100 Gy to the
tumor-encompassing isodose [1]. Consequently, peritu-
moral doses may have been higher than were reported
in Japanese patients, who mainly received a prescription
of a dose of 48 Gy to the tumor isocenter [4, 5, 15–17].
Table 2 Surgical outcome
N (%) or Median (range)
Type of resection
- Lobectomy
- Sleeve-lobectomy
- Pneumonectomy
- Wedge resection
6 (67 %)
1 (11 %)
1 (11 %)
1 (11 %))
Intra-operative findings
- No adhesions
- Limited adhesions
- Extensive adhesions
4 (44 %)
3 (33 %)
2 (22 %)
pTNM
- T1N0
- T2N0
- T1N2
- T2N2
- T3N0
- T3N2
- T4N0
2 (22 %)
2 (22 %)
1 (11 %)
1 (11 %)
1 (11 %)
1 (11 %)
1 (11 %)
Radicality of resection
- R0
- R2
8 (89 %)
1 (11 %)
Surgical complications
- None
- Grade 2
- Grade 3a
6 (67 %)
2 (22 %)
1 (11 %)
Length of hospital stay (days) 8 (5–15)
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As such, the low rate of observed post-operative compli-
cations in our report are reassuring, and consistent with
those reported previously. Surgery may also have been
well tolerated due to the fact that all our cases, as well
as 9 of 12 reported by Hamaji et al, were considered to
be fit to undergo surgery at the time of their initial treat-
ment with SABR [5]. These authors initially attempted a
VATS approach in six patients, but conversion to open
thoracotomy was needed in one patient because of intra-
operative findings [5]. They also covered the bronchial
stump with a pericardial fat pad in two patients and
intercostal muscle in one. Besides a postoperative air
leak exceeding 5 days seen in three patients, no postop-
erative complications were noted in the Japanese series.
In that aspect it is important to realize that all patients
in our series had been treated for peripheral lesions, and
therefore the radiation dose to the ipsilateral proximal
bronchial tree had been relatively low. The results of this
study therefore cannot be generalized to more centrally
located lesions.
The recent changes in patterns of care for patients with
early-stage NSCLC are reflected in the increasing num-
bers of potentially operable patients being referred for
SABR [6, 18]. Even though randomized controlled trials
comparing surgery and SABR in operable patients have
failed to complete accrual [19], several studies using pro-
pensity score matching, matched pair analysis, Markov
modeling and meta-analytic methodologies for patients
with early stage NSCLC reveal comparable outcomes for
both treatment modalities [20, 21]. At present, nearly half
of all Dutch pulmonologists consider surgery and SABR
to be comparable treatments in patients with early-stage
NSCLC [22]. As such, distinguishing commonly observed
benign fibrosis from early tumor recurrence will become
increasingly important. Although radiological features
suggestive of a local recurrence have been identified [23],
both radiologists and radiation oncologists were less profi-
cient in identifying recurrences, than by using image tex-
ture analysis (so-called radiomics) [24]. This suggests that
image texture analysis may have a growing role in evaluat-
ing post-SABR radiology. ESMO guidelines recommend
performing both a new 18FDG-PET scan and a biopsy of
the suspected recurrence [1], as reports of benign lesions
being excised after SABR are not uncommon [17, 25, 26].
The four patients in our series who underwent surgery
without a biopsy reflects, in part, the fact that they were
treated before the ESMO guidelines were published.
A number of key limitations of our study must be ac-
knowledged. This study may not give a true incidence of
surgical salvage for local failures after SABR as a large
proportion of patients treated at both our centers were
referred from the rest of the Netherlands. Consequently,
some patients may have been operated upon elsewhere
without our knowledge. Furthermore, only a minority of
patients who undergo SABR are in fact medically oper-
able, and all our patients represent cases of peripheral
lung tumors, where central hilar and vascular structures
did not receive significant doses of radiation. Conse-
quently, the risks of post-operative complications could
in fact be higher in a typical SABR population. We
would suggest referral to expert surgical centers for such
cases, until such time that broader experience becomes
available.
In conclusion, following SABR for a peripheral NSCLC,
radiological follow-up can allow for the timely detection
and surgical excision of isolated local failures. Additional
data to define optimal surgical approaches for such pa-
tients is awaited, as well as data in patients with more cen-
trally located tumors.
Conclusion
We report our experience with nine surgical procedures
for local recurrences post-SABR. Our analysis revealed
two grade IIIa complications and a 30-day mortality of
0 %. These results suggest that salvage surgery can be
safely performed after SABR.
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